Personalized therapeutic stories for children after kidney transplant.
Official title: Generating Personalized Stories With Artificial Intelligence for Pediatric Kidney Recipients
Run by Paris Translational Research Center for Organ Transplantation · NCT07532382 · Data updated 2026-11-12
We will test whether clinician-supervised AI can create age-appropriate, personalized therapeutic stories for children aged 5–12 who have received a kidney transplant and their families.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 5 Years to 12 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Paris Translational Research Center for Organ Transplantation Academic / other |
| Locations | 1 site (Paris, Île-de-France Region) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | December 1, 2026 |
| Study ends | December 1, 2026 |
| Registry record updated | April 15, 2026 |
| Trial ID | NCT07532382 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 5–12 who have received a kidney transplant, are clinically stable, fluent in French or English, and whose parents/guardians can provide consent and commit to study visits are ideal candidates.
✕Probably not a fit
Children with severe cognitive impairment, an unstable clinical course (such as active rejection or hospitalization), families unable to participate in interviews, or non–French/English speakers are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project develops an AI-assisted workflow that uses large language models to generate age-adapted, personalized therapeutic stories for pediatric kidney transplant recipients and their families. Clinicians supervise story generation and tailor content via interviews and iterative feedback to ensure medical accuracy and emotional safety. Participants aged 5–12 who are clinically stable and fluent in French or English will receive AI-generated stories and be followed for acceptability, usability, and psychosocial outcomes. The study is conducted at Necker Hospital in Paris and focuses on feasibility and refinement rather than testing clinical efficacy.
Why it matters
Potential benefit: If successful, the approach could provide a scalable, clinician-approved way to help children process transplant experiences, reduce anxiety, and support family communication.
How similar studies have gone: Narrative and therapeutic storytelling have shown benefit in pediatric psychosocial care, but the use of clinician-supervised large language models to generate personalized stories for transplant patients is novel and not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 5-12 years inclusive at enrolment. * Recipient of a kidney transplant. * Clinically stable at enrolment (no active rejection, acute infection, or current hospitalization for a graft-related complication). * Fluency in French or English. * Written informed consent from parent(s)/legal guardian(s); child assent when age-appropriate. Exclusion Criteria: * Severe cognitive impairment precluding engagement with narrative content. * Mental state not allowing participation. * Family unwilling or unable to commit to the study timeline and interview requirements.
Where it's running
-
Necker hospital
Paris, Île-de-France Region, France Recruiting
Study contacts
- Principal investigator: Marc Raynaud, PhD — Paris Institute for Transplantation and Organ Regeneration
- Study coordinator: Marc Raynaud, PhD
- Email: mrayna06@gmail.com
- Phone: +33613493009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Omnisol-preserved kidneys before transplant (hypothermic machine perfusion)
This study tests whether using Omnisol during hypothermic machine perfusion before kidney transplant can improve early graft function compared with standard preservation.
-
How Propofol and Sevoflurane Affect miRNA in Living Kidney Donors
This study tests whether using propofol or sevoflurane during donor nephrectomy changes levels of miRNAs in living kidney donors.
-
Effects of general vs spinal-epidural anesthesia on kidney transplant biomarkers
This study tests whether sevoflurane general anesthesia or combined spinal-epidural anesthesia changes markers of cellular stress and protective peptides in adults undergoing kidney transplantation.
-
How kidney transplant patients feel about using artificial intelligence in medicine
This international survey asks adults who have had a kidney transplant how they feel about AI tools that predict graft loss and what it might mean for their daily care.
-
Treating blood vessel problems after a kidney transplant
This effort will try catheter-based angioplasty and advanced imaging to see if they help kidney transplant recipients with graft dysfunction or stubborn high blood pressure from possible transplant blood‑vessel problems.
-
AIC263029 in kidney transplant recipients with BK virus infection
This trial tests whether AIC263029 is safe and tolerable and can lower BK virus levels in adults who recently had a kidney transplant and have BK viremia, compared with placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.